Monoclonal antibodies (mAbs) are nature's biological warheads, able to target and help eliminate foreign or abnormal agents from the body. In theory, replicating this powerful defense system could ...

Monoclonal antibodies (mAbs) can achieve unparalleled affinity and specificity for a wide range of biomolecules, making the reagents critical to both basic and clinical research. The vast majority ...

Published in the peer-reviewed journal mAbs, the study presents nipocalimab's high-affinity binding to the neonatal Fc receptor (FcRn) and its capability to significantly reduce IgG levels ...

During the last three months, 5 analysts shared their evaluations of Y-mAbs Therapeutics (NASDAQ:YMAB), revealing diverse outlooks from bullish to bearish. In the table below, you'll find a ...

Monoclonal antibodies (mAbs) are medications that target specific proteins to help reduce inflammation in people with severe asthma. The FDA has approved six mAbs for asthma treatment so far.

Y MABS THERAPEUTICS ($YMAB) is expected to release its quarterly earnings data on Tuesday, March 4th before market open, per Finnhub. Analysts are expecting revenue ...